Details

Autor(en) / Beteiligte

• Chiriaco, Cristina
• Donini, Chiara
• Cortese, Marco
• Ughetto, Stefano
• Modica, Chiara
• Martinelli, Ilaria
• Proment, Alessia
• Vitali, Letizia
• Fontani, Lara
• Casucci, Monica
• Comoglio, Paolo Maria
• Giordano, Silvia
• Sangiolo, Dario
• Leuci, Valeria
• Vigna, Elisa

Titel

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy

Ist Teil von

• Journal of experimental & clinical cancer research, 2022-10, Vol.41 (1), p.1-309, Article 309

Ort / Verlag

London: BioMed Central Ltd

Erscheinungsjahr

2022

Quelle

Springer Nature - Complete Springer Journals

Beschreibungen/Notizen

• Background Aberrant activation of the MET receptor in cancer is sustained by genetic alterations or, more frequently, by transcriptional upregulations. A fraction of MET-amplified or mutated tumors are sensible to MET targeting agents, but their responsiveness is typically short-lasting, as secondary resistance eventually occurs. Since in the absence of genetic alterations MET is usually not a tumor driver, MET overexpressing tumors are not/poorly responsive to MET targeted therapies. Consequently, the vast majority of tumors exhibiting MET activation still represent an unmet medical need. Methods Here we propose an immunotherapy strategy based on T lymphocytes expressing a Chimeric Antigen Receptor (CAR) targeting MET overexpressing tumors of different histotypes. We engineered two different MET-CAR constructs and tested MET-CAR-T cell cytotoxic activity against different MET overexpressing models, including tumor cell lines, primary cancer cells, organoids, and xenografts in immune-deficient mice. Results We proved that MET-CAR-T exerted a specific cytotoxic activity against MET expressing cells. Cell killing was proportional to the level of MET expressed on the cell surface. While CAR-T cytotoxicity was minimal versus cells carrying MET at physiological levels, essentially sparing normal cells, the activity versus MET overexpressing tumors was robust, significantly controlling tumor cell growth in vitro and in vivo. Notably, MET-CAR-T cells were also able to brake acquired resistance to MET targeting agents in MET amplified cancer cells carrying secondary mutations in downstream signal transducers. Conclusions We set and validated at the pre-clinical level a MET-CAR immunotherapy strategy potentially beneficial for cancers not eligible for MET targeted therapy with inhibitory molecules, including those exhibiting primary or secondary resistance. Keywords: MET oncogene, Immunotherapy, CAR, Targeted therapy, Gastric cancer